VivoSim Prices $4M At-the-Market Private Placement at $0.85 Amid Cash Crunch
VIVS is trading near its 52-week low of $0.78 (2.6% below the low) on elevated volume (60× avg).
Summary
VivoSim Labs priced a $4.0 million private placement at $0.85 per share — a slight premium to the current $0.76 price — with a single healthcare-focused institutional investor. The deal includes 4.7 million shares and warrants for an equal number of shares, exercisable at $0.85 upon shareholder approval. Additionally, existing May 2024 warrants for 520,833 shares will be repriced from $9.60 to $0.85, further diluting existing holders. This follows the July 14 10-K that disclosed a going concern warning, a stockholders' deficit, and a cash balance insufficient to fund operations for the next year. The $4 million infusion is critical for near-term survival but comes at the cost of significant dilution for a company with a market cap of only $3 million. The offering is expected to close July 17.
At the time of this announcement, VIVS was trading at $0.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3M. The 52-week trading range was $0.78 to $5.30. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.